Chemotherapy-induced intestinal epithelial damage directly promotes galectin-9-driven modulation of T cell behavior
Suze A. Jansen,
Alessandro Cutilli,
Coco de Koning,
Marliek van Hoesel,
Cynthia L. Frederiks,
Leire Saiz Sierra,
Stefan Nierkens,
Michal Mokry,
Edward E.S. Nieuwenhuis,
Alan M. Hanash,
Enric Mocholi,
Paul J. Coffer,
Caroline A. Lindemans
Affiliations
Suze A. Jansen
Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht 3584CS, the Netherlands; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands
Alessandro Cutilli
Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands; Center of Molecular Medicine, University Medical Center Utrecht, Utrecht 3584CG, the Netherlands
Coco de Koning
Princess Máxima Center for Pediatric Oncology, Utrecht 3584CS, the Netherlands; Center for Translational Immunology, University Medical Center Utrecht, 3584GX Utrecht, the Netherlands
Marliek van Hoesel
Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands
Cynthia L. Frederiks
Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands; Center of Molecular Medicine, University Medical Center Utrecht, Utrecht 3584CG, the Netherlands
Leire Saiz Sierra
Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands
Stefan Nierkens
Princess Máxima Center for Pediatric Oncology, Utrecht 3584CS, the Netherlands; Center for Translational Immunology, University Medical Center Utrecht, 3584GX Utrecht, the Netherlands
Michal Mokry
Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands; Department of Cardiology, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands
Edward E.S. Nieuwenhuis
Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands; University College Roosevelt, Utrecht University, Middelburg 4331CB, the Netherlands
Alan M. Hanash
Departments of Medicine and Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA
Enric Mocholi
Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands; Center of Molecular Medicine, University Medical Center Utrecht, Utrecht 3584CG, the Netherlands
Paul J. Coffer
Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands; Center of Molecular Medicine, University Medical Center Utrecht, Utrecht 3584CG, the Netherlands; Corresponding author
Caroline A. Lindemans
Division of Pediatrics, University Medical Center Utrecht, Utrecht 3584GX, the Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht 3584CS, the Netherlands; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht 3584CT, the Netherlands; Corresponding author
Summary: The intestine is vulnerable to chemotherapy-induced damage due to the high rate of intestinal epithelial cell (IEC) proliferation. We have developed a human intestinal organoid-based 3D model system to study the direct effect of chemotherapy-induced IEC damage on T cell behavior. Exposure of intestinal organoids to busulfan, fludarabine, and clofarabine induced damage-related responses affecting both the capacity to regenerate and transcriptional reprogramming. In ex vivo co-culture assays, prior intestinal organoid damage resulted in increased T cell activation, proliferation, and migration. We identified galectin-9 (Gal-9) as a key molecule released by damaged organoids. The use of anti-Gal-9 blocking antibodies or CRISPR/Cas9-mediated Gal-9 knock-out prevented intestinal organoid damage-induced T cell proliferation, interferon-gamma release, and migration. Increased levels of Gal-9 were found early after HSCT chemotherapeutic conditioning in the plasma of patients who later developed acute GVHD. Taken together, chemotherapy-induced intestinal damage can influence T cell behavior in a Gal-9-dependent manner which may provide novel strategies for therapeutic intervention.